PR Newswire·Sep 4, 2026, 8:30 AM ET

Alexandria Real Estate Equities, Inc. Highlights Its Role in Advancing Blood Cancer Innovation by Enabling Life-Changing Tenant R&D, Mission-Critical Philanthropic Initiatives and Strategic Investments

ARE

Alexandria Real Estate Equities, Inc. recognizes Blood Cancer Awareness Month by highlighting its strategic investments & tenants developing therapies in hematology & oncology.
Blood cancers account for 9.4% of all new cancers in the U.S. in 2025, with a diagnosis occurring every three minutes & a death every nine minutes.
CEO Peter Moglia states that while survival rates have improved with over one million people living with or in remission from blood cancers, continued investment & collaboration remain essential.
Juno Therapeutics, a longstanding Alexandria tenant in Seattle, advanced the science behind Breyanzi®, an FDA-approved CAR-T cell therapy for relapsed or refractory B-cell blood cancers.
Alexandria Venture Investments was an early investor in Juno, which had a 2014 IPO market capitalization of approximately $2.2 billion before being acquired by Celgene in 2018 & subsequently by Bristol Myers Squibb in 2019.
Alexandria has engaged with nonprofits including the Multiple Myeloma Research Foundation (MMRF), Blood Cancer United, the National Marrow Donor Program (NMDP), Fred Hutch Cancer Center, Memorial Sloan Kettering Cancer Center, & others for over a decade.
The company supports the MMRF at its Blood Cancer Awareness event at the Alexandria Center® for Life Science – New York City megacampus & partners with NMDP to connect patients to life-saving donors.
Alexandria employees utilize company-provided Volunteer Time Off to donate blood, platelets, or bone marrow, & the company coordinates blood drives across its collaborative campuses for employees & tenants.
Founded in 1994, Alexandria Real Estate Equities, Inc. is an S&P 500® REIT & the preeminent owner, operator, & developer of collaborative Megacampus™ ecosystems in AAA life science clusters.